Analysts think EXEL stock price could increase by 27%
Aug 05, 2025, 11:25 AM
0.41%
What does EXEL do
Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
21 analysts think EXEL stock price will increase by 27.43%. The current median analyst target is $46.92 compared to a current stock price of $36.82. The lowest analysts target is $36.36 and the highest analyst target is $63.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.